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Summary
Recurrent events data are frequently encountered in clinical trials. This article develops robust
covariate-adjusted log-rank statistics applied to recurrent events data with arbitrary numbers of events
under independent censoring and the corresponding sample size formula. The proposed log-rank
tests are robust with respect to different data-generating processes and are adjusted for predictive
covariates. It reduces to the Kong and Slud (1997, Biometrika 84, 847–862) setting in the case of a
single event. The sample size formula is derived based on the asymptotic normality of the covariate-
adjusted log-rank statistics under certain local alternatives and a working model for baseline
covariates in the recurrent event data context. When the effect size is small and the baseline covariates
do not contain significant information about event times, it reduces to the same form as that of
Schoenfeld (1983, Biometrics 39, 499–503) for cases of a single event or independent event times
within a subject. We carry out simulations to study the control of type I error and the comparison of
powers between several methods in finite samples. The proposed sample size formula is illustrated
using data from an rhDNase study.
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1. Introduction
Many clinical trials and observational studies involve the study of events that may occur
repeatedly for individual subjects. Examples of such recurrent events data include time to
hospitalization for nonfatal events or resuscitated cardiac arrest. In such data, the numbers of
events are different across patients and are unknown before the clinical trial. Among the
methods for treatment comparisons within the recurrent events data setting, a robust log-rank
test proposed by Lawless and Nadeau (1995), which shares a similar form with the log-rank
test for right censored survival data, is widely used.
In the right censored survival data setting, when some auxiliary information, such as prognostic
covariates or the censoring mechanism, are available, it is well known that an adjusted log-
rank test statistic may improve efficiency, and/or adjust baseline imbalance, compared with
that of the unadjusted log-rank test. The statistical literature contains numerous precedents on
this issue (Tsiatis, Rosner, and Tritchler, 1985; Slud, 1991; Kosorok and Fleming, 1993; Chen
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dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted
log-rank tests. Murray and Tsiatis (2001) considered adjusting a two-sample test for time-
dependent covariates. Mackenzie and Abrahamowicz (2005) used categorical markers to
increase the efficiency of log-rank tests. Kong and Slud (1997) and Li (2001) proposed
covariate-adjusted log-rank tests for two-sample censored survival data. These works motivate
us to consider adjusting covariates in log-rank statistics in the recurrent events setting.
Sample size calculations are critical in the design of clinical trials. In the recurrent event setting,
Hughes (1997) and Bernardo and Harrington (2001) considered power and sample size
calculations based on a multiplicative intensity model and a marginal proportional hazards
model, respectively. Based on the test by Lawless and Nadeau (1995), Cook (1995), and Matsui
(2005) considered sample size calculations in this context via a nonhomogeneous Poisson
process model. Their methods are parametric in the sense that, conditional on a frailty, the
intensity of a homogeneous Poisson process is needed as an input parameter for sample size
calculations.
In this article, we propose a covariate-adjusted log-rank test to improve the power of the tests
and to adjust for random imbalances of the covariates at baseline using a semiparametric
approach. Based on the proposed test, we derive a nonparametric, rather than parametric,
sample size formula based on the limiting distribution of the robust log-rank statistic. The idea
is to base power on the corresponding proportional means local alternatives and a class of
working models for the baseline covariates. This method allows for arbitrary numbers of events
within subject and arbitrary independent censoring distributions.
Numerical studies show that the sample size derived from our method can maintain the type I
error and achieve the desired power. Both the log-rank statistic and the sample size formula
are implemented in the R software package (see www.r-project.org). The remainder of the
article is organized as follows. In Section 2, we present the data structure and the model
assumptions. We describe the robust covariate-adjusted log-rank statistic for recurrent events
and its asymptotic distribution in Section 3. We provide the sample size formula in Section 4
and consider some design issues in Section 5. The relationship to current existing sample size
formula is discussed in Section 6 and some simulation results are reported in Section 7. The
methods are applied to the rhDNase study in Section 8. A discussion concludes the article in
Section 9.
2. The Data and Model Assumptions
Assume that there are n = n1 + n2 independent subjects assigned to two treatments with nj
subjects assigned to treatment j, j = 1, 2. The observed data are {(Tij, Cij, Vij), i = 1, …, nj, j =
1, 2}, where, for subject i within treatment group j, Tij ≡ (Tij1, Tij2, …), where Tij1 < Tij2 <…
are the ordered event times of interest which constitute the recurrent event process. Cij is a
univariate right censoring time. Vij is a p-dimensional covariate which could be time varying.
We also define Kij ≡ max {k : Tijk ≤ Cij} to be the total observed number of events for each
subject.
We will also utilize when convenient the following counting process notation: Nijk(t) ≡ I{Tijk
≤ t, Cij ≥ t}, Nij(t) ≡ supk{k : Tijk ≤ t, Cij ≥ t}, or equivalently, . The at risk
process is Yij(t) ≡ I{Cij ≥ t}.  is the probability of subjects under
study at time t in treatment group j. Define  and  as the corresponding underlying
event process versions of Nijk (t) and Nij(t), i.e., . We also define
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 to be the expected number of events for subject i by
time t in treatment group j, given covariate Vij. The following assumptions are needed:
1. We assume that Tij and Cij are independent given Vij for i = 1, …, nj and j = 1, 2.
2. lim n→∞nj/n = pj ∈ (0, 1), for j = 1, 2, and  for some πj, j =
1, 2.
3. Given the covariates {V (s), s ≤ τ0}, where τ0 ≡ sup{t : π1(t)π2(t) > 0} is the maximum
observation time, the cumulative mean functions of events for subjects under study
within the same treatment group are identical, i.e.,
, for i = 1,2, …, nj, t ∈ (0, τ0). The rate function
, for j = 1, 2. Note that the superscript n permits contiguous
alternatives.
4. , for some Λ0 with Λ0(τ0|V (s),
s ≤ τ0) <∞. Λ0(t | V (s), s ≤ t) can be decomposed as Λ0(t)h(V (t); θ0), where Λ0(t) is
an unspecified baseline function. h(V (t); θ0) is a known positive integrable function
containing information of V, and θ0 is an unknown p-dimensional parameter.
 for some π̃j, j = 1, 2, where
, and Θ0 is a neighborhood containing θ.
5. , where ψ
is either cadlag (right-continuous with left-hand limits) or caglad (left-continuous
with right-hand limits) with bounded total variation and η is bounded and zero except
at event times.
Compared with the unadjusted test statistics, h(V (t); θ) carries the information of the covariates
V(t) about the cumulative mean for each individual into the test statistic. An example of the
working model is h(V (t); θ) = exp(θ′V (t)). The choice of the function h(V (t) ; θ) is an interesting
problem and a practical issue. Without loss of generality, assuming that the covariates to be
adjusted are the same as in the correct model, the functional form h(V (t); θ) of these covariates
can be chosen by certain model diagnostic techniques, such as those used in Lin et al.
(2000). When there is a set of finitely many working models hk(V (t); θ) (k = 1, …, K) available,
Kong and Slud (1997) suggested computing the relative efficiency of each covariate-adjusted
score statistic. The heuristic argument suggested that the working model with the maximum
relative efficiency score statistic is the “best” model in the sense that the corresponding
covariate-adjusted test is the most powerful test based upon the K working models under
consideration. A similar idea can be carried out in our setting. As interesting as this issue is, it
is, however, beyond the scope of the current article.
We also note that assumption 5 is a contiguous sequence of models for recurrent event times
that will facilitate the derivation of the sample size formula. Such contiguous sequences are
routinely used to derive first-order sample size formulas (Schoenfeld, 1983; Gangnon and
Kosorok, 2004, for example). We will sometimes omit the superscript n for notational
simplicity.
3. The Covariate-Adjusted Log-Rank Tests for Recurrent Events Data
To test H0: Λ1(t | V (s), s ≤ t) = Λ2(t | V (s), s ≤ t), t ∈ (0, τ0), the robust log-rank test we propose
takes the form:
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where , and Ŵn is caglad or cadlag with total bounded variation and is
nonnegative so that Ln is sensitive to ordered alternatives. We assume supt ∈ (0, τ0)|Ŵn(t) − W
(t) |→ 0 in probability for some uniformly bounded integrable function W(t).
, j = 1, 2. θ ̂n satisfies the score equation D(θ ̂n) = 0, with
(1)
where h(1)(V (t);θ) is the first derivative of h(V (t); θ) with respect to θ, and
.
Under some regularity assumptions, it can be shown similarly as in Struthers and Kalbfleisch
(1986) that, θ ̂n is consistent for θ★, the unique solution to
For variance estimation, we use the following robust variance estimator:
where , i = 1, …, nj, j = 1, 2 and j′ = 3 −
j.
We also need to assume that , as n → ∞, for some 0< σ2 < ∞, where
and , for i = 1, …, nj, j = 1, 2. Note that this assumption does
not necessarily follow from the assumptions of Section 2 because those assumptions do not
restrict the variability of the recurrent event process.
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We now present two asymptotic results that are needed to derive our sample size formula.
Theorem 1
Under the assumptions 1–5, Ln converges in distribution to a normally distributed random
variable with mean μ and variance σ2, where
Theorem 2
Under the assumptions 1–5,  in probability, as n → ∞.
When there is no need to adjust for covariates, the form of the test statistic and its asymptotic
distribution are similar to that of the weighted log-rank test statistic for clustered survival data
proposed by Gangnon and Kosorok (2004). The differences come from the definition of the at
risk process. In Gangnon and Kosorok (2004), each subject within a cluster has a 0–1 valued
counting process and the same marginal distribution. In contrast, we view the recurrent events
from the same subject as a single counting process. Mij(t) is not a martingale and it follows
that standard martingale methods will not apply anymore. Therefore, the proofs of Theorems
1 and 2 will differ accordingly. Because the processes {Mij(t), i = 1, …, nj, j = 1, 2} and
{ } are manageable
(Pollard, 1990; Bilias, Gu, and Ying, 1997), with the second moment of the total variation
being bounded, we can utilize both Donsker and Glivenko-Cantelli results and the strong
embedding theorem (van der Vaart and Wellner, 1996). Standard empirical process techniques
will then yield the desired results.
4. Sample Size Formulas
We now utilize the asymptotic results of Section 3 to derive sample size formulas based on
appropriate  local alternatives. For convenience, we only consider time independent
covariates V and assume that V and the censoring time C are independent. We also assume that
the treatment indicator is independent of V, which is often the case in randomized clinical trials.
We consider the proportional means local alternative HA: Λj(t | V ) = Λ0(t | V ) exp {(−1)j−1 ψ
(t)/2}, j = 1, 2, ψ(t) ≠ 0, ψ(t) = o(1), t ∈ (0, τ0), and Λ0(t | V ) = Λ0(t)h(V (t);θ). Note that this
alternative satisfies conditions 4 and 5 of Section 2. We now have
Theorem 3
, where
The proof is similar to that of Theorem 1. We note that the approximation exp{ψ(s)/2} − exp
{− ψ(s)/2} ≈ ψ(s) holds only when ψ(s) is very close to zero. For the variance term, the
conclusion of Theorem 2 still holds under the current assumption.
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We now derive the sample size formula for the log-rank test (W(s) = 1). We assume that the
marginal distributions of all the censoring times Cij are identical. Thus π1 = π2 ≡ π0. The baseline
cumulative mean functions are continuous and the local alternatives satisfy ψ = γ, with γ ∈
ℛ.
Corollary 1
μ1 = γp1p2D1g + o(γ), where .
Because π1(s) = π2(s) according to the assumption, pjπj(s)/{p1π1(s) + p2π2(s)} = pj, j = 1, 2,
and η(s) = 0 almost everywhere, Corollary 1 follows automatically. D1g can be interpreted as
the average number of observed events per person across the two treatment groups adjusted
for covariates V, because
D1g can be estimated by the geometric mean
where , j = 1, 2. In order to compute the
asymptotic variance, we assume that  is, conditional on a positive, latent real random variable
ωij and covariates Vij, a nonstationary Poisson process with cumulative intensity function wij




, and j′ ≡ 3 − j.
The proof is deferred to the Web Appendix. When p1 = p2 = 0.5, D1a and D2 are the average
number and the average squared number of observed events among the two treatment groups
conditional on covariates V. They can be estimated by the empirical versions
, and . For the estimation of
, one could adopt quasi-likelihood methods as in Moore and Tsiatis (1991). However, we
use instead a simpler moment estimator
, where x+ denotes the maximum of x and
0. The derivation is in the Web Appendix. Therefore, the sample size required for the alternative
ψ = γ for a two-sided test of size α1 and power α2 is
Song et al. Page 6














When the effect size γ is small, D1g ≈ D1a, the sample size formula (2) has another
approximation form:
When the covariate V has a negligible effect on the mean frequency function, and there is no
within-subject heterogeneity, i.e.,  is 0, this formula reduces to Schoenfeld’s (1983) formula.
D1g, D1a, and D2 need to be estimated, possibly from pilot data that have similar outcomes to
the clinical trial being designed but with shorter follow-up. The value  can be readily
estimated from such pilot data, because this quantity is uncorrelated with the study length.
Consistent with the extra-Poisson nonstationary process assumption, we assume that there are
two components of error. They are the error D1a from a Poisson process and an extraneous
variance part . We may consider that the extraneous variance is caused by the unmeasured
event dependence within subject. Thus the variance is larger than assumed by a pure Poisson
process, which will lead to a larger sample size estimate than the independent events situation.
We notice that in some biological processes, the heterogeneity within subject may have an
opposite effect, which could lead to a shrinkage of the total variance. In this setting, our sample
size formula will overestimate the sample size. Further research is needed to fully take
advantage of the shrinkage variance structure, but this is beyond the scope of the present article.
5. Some Design Issues: Planning the Duration
We assume, for now, uniform recruitment of patients over the first τa years of the trial with a
constant recruitment rate ρ. The total expected number of patients is thus ρτa. The goal of this
section is to show how one can estimate the accrual time τa required to achieve power α2 at a
given type I error level α1, for a specified rate ρ.
Let Rij denote the real randomization time for each patient, and assume Rij is independently
uniformly distributed on [0, τa]. Similar to what was done in Theorem 3, we can show that
, where .  is the updated version of D1g under the
current trial setting. When τa is known, it can be estimated by
Correspondingly, define , and
, j′ ≡ 3 − j. These quantities can be estimated by the
following updated versions of D ̂1a and D ̂2:
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Under the previous extra-Poisson variation assumption, . A
simple moment estimator of  is thus
Now τa can be obtained from the following self-consistency equation using the line search
method:
(3)
6. Relationship to Current Existing Formula Based on Unadjusted Log-Rank
Statistic
When covariates are not adjusted, Cook (1995) described a method for planning the duration
of a randomized parallel group study in which the response of interest is potentially recurrent
events data. Cook assumed patients accrue at a constant rate ρ in an accrual period of duration
τa years with M denoting the random sample size and m the corresponding realization. At the
end of the accrual period, subjects were assumed to be followed for an additional length of
time τc, called the continuation period. τ = τa + τc was defined as the total study duration. The
recurrent events the patients experienced over the whole study time were assumed to follow a
homogeneous Poisson process with intensity λj, j = 0, 1. A proportional intensity model of the
form λ(zi) = λ exp{βzi} was considered, where λ = λ0 and β = log {λ1/λ0}, with zi = 0, 1 denoting
the treatment group membership. The censoring time was assumed to be exponential with rate
δj. They derived the sample size formula based on the score tests on the regression coefficient
β with respect to the hypothesis H0 : β = 0 versus H1: β = βa.
Cook (1995) also considered extra-Poisson variation and proposed a revision of the variance
in the original formula derived under the homogeneous Poisson process assumption. Cook
(1995) used this to derive a revised variance to account for extra Poisson variation which leads
to a different approximation from ours. Cook (1995) did not provide a method for estimating
the extra-Poisson variance.
Proposition 1
When there are no covariates adjusted, under the parametric settings in Cook (1995) and under
the same assumptions about accrual time, duration time, and censoring rate, the difference
between our sample size estimate n′ and Cook’s estimate m is
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where k(δ, τa, τc) > 1 is a function of the censoring rate δ, the accrue time τa and the duration
time τc. Thus n′ > m when .
The proof is deferred to the Web Appendix.
When , Cook’s variance achieves the Cramer–Rao information lower bound and is
efficient. Our sample size formula boils down to Cook’s under the same parametric setting.
When there exists heterogeneity within subject, Cook (1995) treated the quantities
 as the maximum likelihood estimators of λj, where  and  represent the total
number of events and the total person years on treatment j, j = 0, 1. λ̃j was plugged into the
original score test statistic, and the sample size was derived after applying the delta method
and a series approximation. Although λ̃j is the true maximum likelihood estimate under the
homogeneous Poisson model, this is not true in the presence of overdispersion, as pointed out
in their paper. Thus their estimate is not in general a maximum likelihood estimate and may
be inconsistent.
Matsui (2005) also considered sample size calculations with overdispersed Poisson data. His
method is also parametric in the sense that λj is needed as an input parameter for sample size
calculations. Compared with the model setting in Cook (1995) and Matsui (2005), our approach
uses minimal assumptions about the data-generation process. Moreover, our sample size
formula is derived based on the asymptotic normality of the covariate-adjusted log-rank test
statistic. Thus our approach is more robust. In addition, we have an asymptotically unbiased
estimator of the variance of the log-rank statistic, based on the estimated second moment of
the cumulative mean function rather than on the square of the expected cumulative mean
function as done in Cook. Therefore, our sample size is larger than Cook’s in the presence of
overdispersion, as it should be.
7. Simulation Studies
The simulation study was designed in two parts. In the first part of the simulation, we study
the small sample properties of the covariate-adjusted and unadjusted test statistics using
simulations from overdispersed homogeneous Poisson data with intensity λ (t | V ) = λwexp
{ψZ}h(V ;θ). A constant baseline intensity of λ = 0.25 is used. The heterogeneity source w is
generated as a gamma distributed random variable with mean 1 and variance , 0.5, and
1, respectively. The treatment indicator Z takes values 0 and 1 with equal probability. The
covariate V = aZ + ε, where ε follows standard normal distribution. The regression coefficient
a is varied such that the correlation coefficient between V and Z are taken to be 0, 0.3, and
−0.3, respectively. We consider h(V ; θ) = exp(θV ) and take θ to be 0, 0.5, and −0.5,
respectively.
The censoring times follow an exponential distribution with rate λ/5 and the follow-up period
is 3 years. All simulated trials involve nominal two-sided type I error α1 = 0.05. For each
setting, we simulate 2000 data sets with sample size 100 to achieve a Monte Carlo error of 0.01
for the type I error. The empirical powers are evaluated at ψ = log(0.6). The empirical type I
error and the empirical power of the covariates-adjusted and unadjusted tests are recorded in
Table 1.
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When the covariate V has no effect on the time to event, the estimated type I errors are very
close to the nominal levels for both statistics. When V has an effect on the event times, the
empirical type I errors are still close to the nominal levels for both statistics when V and Z are
uncorrelated. Due to the overly high empirical type I errors, the unadjusted log-rank test is not
valid when V and Z are correlated and V has an effect on the event times, while the adjusted
log-rank statistic works fine for this situation.
For the unadjusted tests, we only estimate their power when they are valid tests as indicated
above. It can be seen that when V and Z are uncorrelated, using covariate-adjusted tests can
increase the power, while the power using the unadjusted tests seems higher than the covariate-
adjusted tests when V and Z are correlated and V has no effect on time to event.
In the second part of the simulation, we compare several sample size formulas. Cook (1995)
provided several tables of trial duration and expected sample size for specified powers of two-
sided tests under several scenarios. We borrow a small subset for illustration purpose. All
simulated trials involve nominal two-sided type I error α1 = 0.05 and nominal power α2 = 0.80.
The subjects are randomized to each treatment with equal probability. A constant baseline
intensity of λ = 0.25 is used. We show the results from trials with no continuation period, 0.5
and 1 year continuation periods. No censoring and heavy censoring from an exponential
distribution with rate δ0 = δ1 = λ/5 are presented. For each setting, we simulate 2000 data sets
to achieve a Monte Carlo error of 0.01 for the type I error. Instead of computing the accrual
time at the given accrual rate and duration period, we use the computed accrual period and
duration period in Cook’s paper to compute the sample size in order to make the comparison
of sample sizes more direct.
Because our sample size formula is identical with Cook’s when there is no event dependence
and constant intensity, we only implement simulations to study the behavior of the methods
for overdispersed homogeneous Poisson data. The heterogeneity source w is generated as a
gamma distributed random variable with mean 1 and variance , 2 and 3, respectively. We
simulate data with β = 0 for evaluating type I error rates and β = log(0.6) for evaluating power.
Table 2 records the empirical type I error and the empirical power at the corresponding sample
size. Our sample size is larger than Cook’s, which, based on discussions in the previous section,
is as expected. Both methods can maintain the nominal type I error of 5%. When the extra-
Poisson variance increases, the power of Cook’s method is smaller than the nominal level of
power, while ours performs better. This is because we have a consistent estimate of the average
squared mean intensity, which is underestimated in Cook (1995).
8. Example: rhDNase Study
We will illustrate the test and the sample size formula through the following example. A
randomized double-blind trial was conducted by Genentech Inc. (South San Francisco, CA),
in 1992 to compare rhDNase to placebo (Fuchs et al., 1994). Recombinant DNase I (rhDNase
or Pulmozyme) was a treatment cloned by Genentech Inc., to reduce the viscoelasticity of
airway secretions and improve mucus clearance in the lung of cystic fibrosis patients.
The study enrolled 645 patients. Enrollment lasted from December 31, 1991 until March 31,
1992. The follow-up time of patients extended from March 20, 1992 to September 24, 1992.
During the time patients were monitored for pulmonary exacerbations and data on all
exacerbations and the baseline level of forced expiratory volume in 1 second (FEV1) were
recorded. The primary endpoint was the time until first pulmonary exacerbation (Fuchs et al.,
1994). The data were analyzed by Therneau and Hamilton (1997) to compare several
semiparametric methods for recurrent events data. Both the treatment effect and baseline
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FEV1 are shown to be significant. Here we are interested in testing the treatment effect in terms
of reducing the number of exacerbations viewed as recurrent events and calculating the sample
size based on the log-rank test, for both FEV1-adjusted and unadjusted versions.
A two-sided type I error rate of 5% and power of 80% are considered here. We test a log-rate
ratio of −0.345 (or a rate ratio of 0.708), which is estimated using the marginal model by Wei,
Lin, and Weissfeld (1989) as recommended in Therneau and Hamilton (1997). θ ̂n = −0.194 by
solving (1). As pointed out in Section 4, we also need the extra Poisson variance , the
expected number of events D1g, D1a and the expected squared number of events D2 to get the
sample size. We take several looks during the trial as recorded in part (i) of Table 3. We consider
the trial period before each monitoring time as artificial pilot studies in order to extract the
desired information. We then apply those parameter estimates to obtain the sample size for the
“real” trial. By “real,” we mean the completed trial based on the actual monitoring times.
As noted earlier, the values of D1g, D1a, and D2 depend on the censoring distribution and the
real study length in addition to the event time distribution. Hence there is no unified,
nonparametric method to specify them prior to the trial. The quantities could be determined
by the investigator’s prior knowledge or biological reasoning, but this may differ according to
different trial settings. As indicated in Figure 1, in this trial the timing of patient enrollment
and dropout is roughly exponentially distributed and the length of follow-up time of most
patients is about 165 days. We further examined the expected number of events and the
expected squared number of events in Figure 2. The roughly straight lines in the left graph
show that the event process appears to roughly follow a homogeneous Poisson assumption,
and the approximate quadratic lines in the right graph are consistent with this presumption.
Considering the above two facts, we apply linear extrapolation to estimate D1g, D1a and
quadratic extrapolation for D2 of the real trial using their values from the pilot study. This
extrapolation procedure is generally applicable to approximately homogeneous Poisson data
under uniform censoring.
For illustration, we consider the first analysis date of May 9, 1992. The estimate of  is 0.160
based on the data collected prior to that time. The observed D ̂1g, D ̂1a, and D ̂2 are 0.190, 0.192,
and 0.056 at that time, respectively. Dividing by the average trial time 62 up to May 9, 1992
and multiplying by the average total trial time 165, we obtain the projected D ̂1g = 0.512 and
D ̂1a = 0.519. The value D ̂2 = 0.410 at the end of trial is obtained from the current D ̂2 times the
squared ratio of 165 over 62. Therefore, the sample size is estimated as 586 using the “pilot”
study data. The sample size using the information from the whole study is 584. The estimated
extra Poisson variance is distributed uniformly around the value at the end of the study, 0.314,
at each look, which supports the extra-Poisson variation assumption. At each look, we carry
out the robust covariate-adjusted log-rank test. The p-values turn out to mostly decrease as the
study length increases, as expected.
In the same manner, we evaluate the covariate unadjusted log-rank tests and calculate the
corresponding sample size formulas, recorded in part (ii) of Table 3. Interestingly, the estimated
variance of frailty w is larger than these FEV1 adjusted estimates, which indicates that partial
event dependence within a subject can be interpreted through the effect of FEV1. The smaller
sample needed is the main advantage of the adjusted test versus unadjusted test in this
application. Although the adjusted and the unadjusted tests show similar results, the adjusted
tests always produce slightly more significant results than those from the unadjusted tests,
suggested by the smaller p-values. The estimated sample sizes based on the covariate
unadjusted tests are higher than these based on the covariate adjusted tests, as expected.
We note that, although the pilot study and the real study are connected in this example, this is
not necessary in practice. This was just done in this instance to illustrate a possible approach
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to estimating D1g, D1a, and D2. Other approaches could be used in other settings in order to
meet the required power, economic, and practical constraints.
9. Discussion
In this article, we propose a covariate-adjusted robust log-rank test. The proposed log-rank
tests are robust with respect to different data-generating processes and adjustments for
covariates. It reduces to Kong and Slud (1997) in the case of a single event. We also provide
a sample size formula based on the asymptotic distribution of the robust covariate-adjusted
log-rank test statistic and a method of estimating the extra Poisson variance. Compared with
Cook (1995) and Matsui (2005), an advantage of our sample size formula is that it is
nonparametric and more robust to the data-generation process. Simulation studies validate our
proposed method. An rhDNase study is used to illustrate our method.
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The number of enrolled patients versus the time of entering the study (days) (top left), the
number of patients versus the time of the end of the study (days) (top right), and the number
of patients versus the duration time (days) of patients stay in the study (bottom) in the rhDNase
study.
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The expected number of events (left) and the expected squared number of events (right) over
time in the rhDNase trial. In the left plot, the solid line and the dashed line are combined data
with the geometric mean and with the arithmetic mean, respectively. In the right plot, the solid
line is combined data. In both panels, the dotted line is the placebo group, and the dash-dotted
line is the rhDNase group.
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